Baseline characteristics of patients with thoracic neoplasms
| Characteristics | Total (n = 42) | NR (n = 19) | R (n = 23) | P |
|---|---|---|---|---|
| Age, years | 0.769 | |||
| <65 | 30 (71.4%) | 14 (73.7%) | 16 (69.6%) | |
| ≥65 | 12 (28.6%) | 5 (26.3%) | 7 (30.4%) | |
| Gender | 1 | |||
| Female | 10 (23.8%) | 5 (26.3%) | 5 (21.7%) | |
| Male | 32 (76.2%) | 14 (73.7%) | 18 (78.3%) | |
| ECOG PS | 1 | |||
| 0 | 1 (2.4%) | 0 (0.0%) | 1 (4.3%) | |
| 1 | 17 (40.5%) | 8 (42.1%) | 9 (39.1%) | |
| 2 | 24 (57.1%) | 11 (57.9%) | 13 (56.5%) | |
| Smoking status | 0.453 | |||
| Nonsmoker | 13 (31.0%) | 7 (36.8%) | 6 (26.1%) | |
| Smoker | 29 (69.0%) | 12 (63.2%) | 17 (73.9%) | |
| Histology | 0.087 | |||
| Lung adenocarcinoma | 15 (35.7%) | 9 (47.4%) | 6 (26.1%) | |
| Lung squamous carcinoma | 23 (54.8%) | 7 (36.8%) | 16 (69.6%) | |
| Other† | 4 (9.5%) | 3 (15.8%) | 1 (4.3%) | |
| Mutation status | 0.122 | |||
| EGFR | 5 (11.9%) | 4 (21.1%) | 1 (4.3%) | |
| ALK | 1 (2.4%) | 1 (5.3%) | 0 (0.0%) | |
| KRAS | 1 (2.4%) | 0 (0.0%) | 1 (4.3%) | |
| WT/unknown | 35 (83.3%) | 14 (73.7%) | 21 (91.3%) | |
| Metastasis sites | 0.125 | |||
| <2 | 14 (33.3%) | 4 (21.1%) | 10 (43.5%) | |
| ≥2 | 28 (66.7%) | 15 (78.9%) | 13 (56.5%) | |
| Number of prior systemic regimens | 0.002* | |||
| <3 | 30 (71.4%) | 9 (47.4%) | 21 (91.3%) | |
| ≥3 | 12 (28.6%) | 10 (52.6%) | 2 (8.7%) | |
| Previous systemic therapy | 0.808 | |||
| Platinum-based therapy | 36 (85.7%) | 16 (84.2%) | 20 (87.0%) | |
| Other systemic therapy | 5 (11.9%) | 2 (10.5%) | 3 (13.0%) | |
| Unknown | 1 (2.4%) | 1 (5.3%) | 0 (0.0%) | |
| Prior radiotherapy | 0.525 | |||
| No | 15 (35.7%) | 8 (42.1%) | 7 (30.4%) | |
| Yes | 27 (64.3%) | 11 (57.9%) | 16 (69.6%) | |
| Usage of ATB | 1 | |||
| No | 40 (95.2%) | 18 (94.7%) | 22 (95.7%) | |
| Yes | 2 (4.8%) | 1 (5.3%) | 1 (4.3%) |
*P < 0.05 was considered significant. †Other included 1 SCLC, 1 NSCLC, 1 thymic squamous carcinoma, and 1 large cell neuroendocrine carcinoma. ATB: antibiotics.